Details for New Drug Application (NDA): 213764
✉ Email this page to a colleague
NDA 213764 describes SACUBITRIL AND VALSARTAN, which is a drug marketed by Alembic, Alkem Labs Ltd, Biocon Pharma, Crystal, Dr Reddys, Laurus, Lupin, Macleods Pharms Ltd, MSN, Torrent, and Zydus Pharms, and is included in eleven NDAs. It is available from seven suppliers. Additional details are available on the SACUBITRIL AND VALSARTAN profile page.
The generic ingredient in SACUBITRIL AND VALSARTAN is sacubitril; valsartan. There are eleven drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the sacubitril; valsartan profile page.
The generic ingredient in SACUBITRIL AND VALSARTAN is sacubitril; valsartan. There are eleven drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the sacubitril; valsartan profile page.
Summary for 213764
| Tradename: | SACUBITRIL AND VALSARTAN |
| Applicant: | Alkem Labs Ltd |
| Ingredient: | sacubitril; valsartan |
| Patents: | 0 |
Pharmacology for NDA: 213764
| Mechanism of Action | Angiotensin 2 Receptor Antagonists Neprilysin Inhibitors |
Suppliers and Packaging for NDA: 213764
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| SACUBITRIL AND VALSARTAN | sacubitril; valsartan | TABLET;ORAL | 213764 | ANDA | Ascend Laboratories, LLC | 67877-707 | 67877-707-51 | 180 TABLET, FILM COATED in 1 BOTTLE (67877-707-51) |
| SACUBITRIL AND VALSARTAN | sacubitril; valsartan | TABLET;ORAL | 213764 | ANDA | Ascend Laboratories, LLC | 67877-707 | 67877-707-60 | 60 TABLET, FILM COATED in 1 BOTTLE (67877-707-60) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 24MG;26MG | ||||
| Approval Date: | Sep 16, 2024 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 49MG;51MG | ||||
| Approval Date: | Sep 16, 2024 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 97MG;103MG | ||||
| Approval Date: | Sep 16, 2024 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
